Premium
Rituximab as monotherapy and in addition to reduced CHOP in children with primary immunodeficiency and non‐Hodgkin lymphoma
Author(s) -
Shabbat Shimrit,
Aharoni Jonas,
Sarid Liat,
BenHarush Miriam,
Kapelushnik Joseph
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21808
Subject(s) - medicine , rituximab , lymphoma , chop , regimen , common variable immunodeficiency , oncology , primary immunodeficiency , chemotherapy , immunodeficiency , immunology , pediatrics , antibody , immune system , disease
Children with primary immunodeficiency or chromosomal breakage syndromes are at increased risk of developing non‐Hodgkin lymphomas; they cannot tolerate standard chemotherapy regimens. We report two children with diffuse, large, B‐cell lymphoma; one had ataxia telangiectasia and one had common variable immunodeficiency. Both were given rituximab, 1 as monotherapy and 1 in combination with a reduced CHOP regimen. Complete remission was obtained in each patient. Use of rituximab as a first‐line monotherapy or in conjunction with reduced chemotherapy should be considered to reduce cytotoxic effects. Pediatr Blood Cancer 2009;52:664–666. © 2009 Wiley‐Liss, Inc.